Higher Dose Epinephrine in Anaphylaxis
Higher doses of epinephrine are used in cardiac arrest (1 mg IV/IO every 3-5 minutes), not in anaphylaxis, where the standard dose is 0.3-0.5 mg intramuscularly. 1, 2
Cardiac Arrest Dosing
The American Heart Association provides a Class 1 (strong) recommendation for administering 1 mg IV/IO epinephrine every 3-5 minutes during adult cardiac arrest for all rhythms (ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity). 1, 2
This standard cardiac arrest dose is 3-5 times higher than the anaphylaxis dose and must be given intravenously or intraosseously rather than intramuscularly. 2, 3
The cardiac arrest dose significantly increases return of spontaneous circulation (ROSC) by 151 more patients per 1,000 compared to placebo (RR 2.80,95% CI 1.78-4.41). 2
No maximum cumulative dose is defined in current guidelines, though cumulative doses above 3 mg may be associated with unfavorable neurological outcomes. 2, 4
Anaphylaxis Dosing (Lower Dose)
For anaphylaxis, the recommended dose is 0.3-0.5 mg (0.3-0.5 mL of 1:1000 concentration) intramuscularly into the mid-anterolateral thigh. 2, 3
This dose may be repeated every 5-15 minutes as needed if symptoms persist. 2, 3
The intramuscular route provides rapid peak plasma concentrations and is preferred for its ease, effectiveness, and safety in anaphylaxis. 3
High-Dose Epinephrine is NOT Recommended
High-dose epinephrine (0.1-0.2 mg/kg) carries a Class 3: No Benefit recommendation for routine use in cardiac arrest. 1, 2
Multiple trials comparing high-dose (0.1-0.2 mg/kg) with standard-dose epinephrine found no improvement in survival to discharge with favorable neurological outcome, survival to discharge, or survival to hospital admission. 1, 5
While high-dose epinephrine may increase short-term ROSC rates, the adverse effects in the post-arrest period negate potential advantages during the arrest. 1
High-dose epinephrine may only be considered in exceptional circumstances such as β-blocker overdose, calcium channel blocker overdose, or when titrated to real-time physiologically monitored parameters. 1, 6
Critical Transition: Anaphylaxis Progressing to Cardiac Arrest
If anaphylaxis causes cardiac arrest, immediately abandon the 0.3-0.5 mg IM protocol and switch to the cardiac arrest regimen of 1 mg IV/IO every 3-5 minutes. 3
During cardiac arrest, peripheral perfusion is essentially absent, making IM absorption unpredictable, and the 0.3-0.5 mg IM dose provides only 30-50% of the dose required for effective cardiac arrest therapy. 3
Standard resuscitative measures and immediate epinephrine administration via IV/IO route take priority over continued IM dosing once the patient becomes pulseless. 3
Common Pitfalls and Error Prevention
The most dangerous error is confusing the 1:1000 concentration (1 mg/mL) used for IM anaphylaxis with the 1:10,000 concentration (0.1 mg/mL) required for IV cardiac arrest dosing. 3, 7
Administering the cardiac arrest dose (1 mg IV push of 1:1000) to an anaphylaxis patient with a pulse can cause transient severe systolic dysfunction and potentially lethal cardiac complications. 7
Hospitals should stock clearly labeled, pre-filled syringes that differentiate "ANAPHYLAXIS – INTRAMUSCULAR ONLY" (1:1000) from "CARDIAC ARREST – IV/IO ONLY" (1:10,000) preparations. 3, 7
A survey revealed that 6 of 7 hospitals lacked pre-filled intramuscular syringes, a gap associated with higher risk of medication errors. 3, 7
Pediatric Dosing Differences
For pediatric cardiac arrest, the dose is 0.01 mg/kg (0.1 mL/kg of 1:10,000 concentration) with a maximum single dose of 1 mg, repeated every 3-5 minutes. 2, 3, 6
For pediatric anaphylaxis, the dose is 0.01 mg/kg (maximum 0.3 mg) intramuscularly using 1:1000 concentration. 3
Vasopressin Offers No Advantage
Vasopressin in combination with epinephrine offers no advantage as a substitute for standard-dose epinephrine in cardiac arrest (Class IIb, Level of Evidence B-R). 1
Multiple trials with 2,402 patients showed no superiority with vasopressin and epinephrine combination for survival to hospital discharge with favorable neurological outcome. 1